CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Tuesday, December 10, 2019 at 6:00 a.m. EST to review highlights from its presentations at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida, on December 7-10, 2019.
- Rami Komrokji, M.D., Senior Member & Professor of Oncologic Sciences, Section Head- Leukemia and MDS, Vice Chair-Malignant Hematology Department, Moffitt Cancer Center, Tampa, Florida
- Thomas Coates, M.D., Professor of Pediatrics and Pathology, Division of Hematology / Oncology, Children’s Hospital Los Angeles, University of Southern California
- Srdan Verstovsek, M.D., Ph.D., Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
The webcast will be accessible under "Events & Presentations" in the Investors & Media page of the company's website at www.acceleronpharma.com. Individuals can participate in the conference call by dialing 877-312-5848 (domestic) or 253-237-1155 (international) and refer to the “Acceleron ASH 2019 Conference Call.”
The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Bristol-Myers Squibb, are co-promoting newly approved REBLOZYL® (luspatercept-aamt), the first and only approved erythroid maturation agent, in the United States and are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes and myelofibrosis. Acceleron is also advancing its neuromuscular program with ACE-083, a locally-acting Myostatin+ agent in Phase 2 development in Charcot-Marie-Tooth disease and is conducting a Phase 2 pulmonary program with sotatercept in pulmonary arterial hypertension.